Project Title	Funding	Strategic Plan Objective	Institution
Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism	$0	Q1.L.A	Centers for Disease Control and Prevention (CDC)
Serum antibody biomarkers for ASD	$570,780	Q1.L.A	University of Texas Southwestern Medical Center
Epigenetic biomarkers of autism in human placenta	$576,142	Q1.L.A	University of California, Davis
Biomarkers for autism and for gastrointestinal and sleep problems in autism	$0	Q1.L.A	Yale University
Identification of lipid biomarkers for autism	$0	Q1.L.A	Massachusetts General Hospital
Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype	$0	Q1.L.A	University of Florida
Placental vascular tree as biomarker of autism/ASD risk	$0	Q1.L.A	Research Foundation for Mental Hygiene, Inc.
A prospective multi-system evaluation of infants at risk for autism	$0	Q1.L.B	Massachusetts General Hospital
Family studies of sensorimotor and neurocognitive heterogeneity in autism spectrum disorders (ASD)	$0	Q1.L.B	University of Texas Southwestern Medical Center
A prospective multi-system evaluation of infants at risk for autism	$0	Q1.L.B	Massachusetts General Hospital
Identifying neurobiological markers of the broader autism phenotype	$106,245	Q1.L.B	University of Melbourne
Receptive vocabulary knowledge in low-functioning autism as assessed by eye movements, pupillary dilation, and event-related potentials	$0	Q1.L.C	Johns Hopkins University
Atypical pupillary light reflex in individuals with autism	$0	Q1.Other	University of Missouri
Characterization of the pathological and biochemical markers that correlate to the clinical features of autism	$0	Q2.Other	Research Foundation for Mental Hygiene, Inc.
MTHFR functional polymorphism C677T and genomic instability in the etiology of idiopathic autism in simplex families	$114,984	Q2.Other	Queen's University
Characterization of the pathological and biochemical markers that correlate to the clinical features of autism	$0	Q2.Other	Research Foundation for Mental Hygiene, Inc.
Self-injurious behavior: An animal model of an autism endophenotype	$0	Q2.Other	University of Florida
Serotonin signal transduction in two groups of autistic patients	$0	Q2.Other	University of Illinois at Chicago
Neural basis of empathy and its dysfunction in autism spectrum disorders (ASD)	$0	Q2.Other	Duke University
Developing novel automated apparatus for studying battery of social behaviors in mutant mouse models for autism	$0	Q2.Other	Weizmann Institute of Science
Role of autism-susceptibility gene, CNTNAP2, in neural circuitry for vocal communication	$0	Q2.Other	University of California, Los Angeles
Characterization of the pathological and biochemical markers that correlate to the clinical features of autism	$0	Q2.Other	Research Foundation for Mental Hygiene, Inc.
Excessive cap-dependent translation as a molecular mechanism underlying ASD	$0	Q2.Other	New York University

Project Title	Funding	Strategic Plan Objective	Institution
How autism affects speech understanding in multitalker environments	$143,264	Q2.Other	University of Maryland, College Park
White matter glial pathology in autism	$145,689	Q2.Other	East Tennessee State University
Systematic characterization of the immune response to gluten and casein in autism spectrum disorders	$0	Q2.S.A	Weill Cornell Medical College
Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development	$0	Q2.S.A	University of Rochester
Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development	$0	Q2.S.A	Arkansas Children's Hospital Research Institute
Mechanisms of mitochondrial dysfunction in autism	$0	Q2.S.A	Georgia State University
Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development	$0	Q2.S.A	State University of New York at Potsdam
Modulation of fxr1 splicing as a treatment strategy for autism in fragile X syndrome	$0	Q2.S.D	Stanford University
The functional link between DISC1 and neuroligins: Two genetic factors in the etiology of autism	$0	Q2.S.D	Children's Memorial Hospital, Chicago
Altered gastrointestinal function in the neuroligin-3 mouse model of autism	$281,742	Q2.S.E	University of Melbourne
Gastrointestinal functions in autism	$0	Q2.S.E	University at Buffalo, The State University of New York
Altered gastrointestinal function in the neuroligin-3 mouse model of autism	$50,434	Q2.S.E	University of Melbourne
Etiology of sleep disorders in ASD: Role of inflammatory cytokines	$0	Q2.S.E	University of Maryland, Baltimore
Altered gastrointestinal function in the neuroligin-3 mouse model of autism	$69,813	Q2.S.E	University of Melbourne
Neural correlates of restricted, repetitive behaviors in autism spectrum disorders	$0	Q2.S.G	Massachusetts General Hospital
Neural correlates of restricted, repetitive behaviors in autism spectrum disorders	$0	Q2.S.G	Massachusetts General Hospital
The transcription factor PLZF: A possible genetic link between immune dysfunction and autism	$0	Q3.L.B	Memorial Sloan-Kettering Cancer Center
Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II	$0	Q3.L.C	Harvard University
Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II	$0	Q3.L.C	Massachusetts General Hospital
Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II	$0	Q3.L.C	Harvard University
Immunopathogenesis in autism: Regulatory T cells and autoimmunity in neurodevelopment	$0	Q3.S.F	East Carolina University
MeHG stimulates antiapoptotic signaling in stem cells	$0	Q3.S.F	Kennedy Krieger Institute

Project Title	Funding	Strategic Plan Objective	Institution
Risk factors, comorbid conditions, and epidemiology of autism in children	$143,162	Q3.S.H	Henry M. Jackson Foundation
Analysis of the small intestinal microbiome of children with autism	$0	Q3.S.I	Massachusetts General Hospital
Discordant monozygotic twins as a model for genetic-environmental interaction in autism	$0	Q3.S.J	Kennedy Krieger Institute
Discordant monozygotic twins as a model for genetic-environmental interaction in autism	$0	Q3.S.J	Johns Hopkins University
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	$0	Q4.L.A	University of Medicine & Dentistry of New Jersey
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Metabolic signature of antipsychotics used in the treatment of autism	$588,750	Q4.L.C	University of Cincinnati
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2	$0	Q4.S.B	Burnham Institute
Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1	$0	Q4.S.B	Burnham Institute
Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders	$0	Q4.S.B	Massachusetts Institute of Technology
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes	$0	Q4.S.B	University of North Carolina at Chapel Hill
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes	$0	Q4.S.B	University of North Carolina at Chapel Hill
Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome	$0	Q4.S.B	University of North Carolina at Chapel Hill
Novel probiotic therapies for autism	$0	Q4.S.B	California Institute of Technology
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes	$0	Q4.S.B	University of North Carolina at Chapel Hill
Novel therapeutic targets to treat social behavior deficits in autism and related disorders	$560,625	Q4.S.B	University of Texas Health Science Center at San Antonio
Examination of the mGluR-mTOR pathway for the identification of potential therapeutic targets to treat fragile X	$542,684	Q4.S.B	University of Pennsylvania
A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder	$1,159,063	Q4.S.C	Massachusetts General Hospital
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital

Project Title	Funding	Strategic Plan Objective	Institution
A randomized clinical trial of cognitive enhancement therapy for adults with autism spectrum disorders	$0	Q4.S.F	University of Pittsburgh
Improving synchronization and functional connectivity in autism spectrum disorders through plasticity-induced rehabilitation training	$0	Q4.S.F	University of California, San Diego
Development of an internet-based parent training intervention for children with ASD	$0	Q5.L.A	Michigan State University
Using technology to expand and enhance applied behavioral analysis programs for children with autism in military families	$0	Q5.L.A	University of Nebraska Medical Center
Evaluating and enhancing driving ability among teens with autism spectrum disorder (ASD)	$214,498	Q6.L.A	University of Iowa
Evaluating and enhancing driving ability among teens with autism spectrum disorder (ASD)	$331,421	Q6.L.A	University of Virginia
Evaluating and enhancing driving skills of individuals with Asperger's and high-functioning autism	$0	Q6.L.A	University of Virginia